BioCentury | Jan 25, 2020
Targets & Mechanisms

CAR T strategies for cracking the code in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...
BioCentury | Jan 23, 2020
Product Development

Thirteen years from founding, Epizyme scores first FDA approval

Despite multiple setbacks over the years, Epizyme now has an approved drug on which to hang its hat and foundational hypothesis. On Thursday, its Tazverik tazemetostat became the first approved therapy to treat epithelioid sarcoma....
BC Extra | Dec 18, 2019
Company News

Dec. 18 Company Quick Takes: FDA approves enfortumab vedotin; plus ODAC roundup, Illumina-PacBio, Benlysta, Ultragenyx, Syros-GBT, Xtandi

Enfortumab vedotin approved for urothelial cancer FDA granted accelerated approval to Padcev enfortumab vedotin-ejfv from Seattle Genetics Inc. (NASDAQ:SGEN) and Astellas Pharma Inc. (Tokyo:4503) to treat locally advanced or metastatic urothelial cancer in adults who...
BC Extra | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

A spate of regulatory news since the start of the Thanksgiving holiday included a drug approval for Chipscreen, a duo of Priority Reviews from FDA, a pair of EMA reviews, and the scheduling of two...
BC Extra | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

Shape raises $35.5M A round  RNA editing company Shape Therapeutics Inc. raised $35.5 million in a series A round led by New Enterprise Associates, with participation from CureDuchenne Ventures. The company uses guide RNAs to...
BC Innovations | Sep 12, 2019
Distillery Therapeutics

Inhibition of G9A and DNMT methyltransferases in bladder cancer

DISEASE CATEGORY: Cancer INDICATION: Bladder cancer Dual inhibition of G9A and DNMT methyltransferases, in combination with cisplatin and anti-programmed cell death 1 ligand 1 (PD-L1), could help to treat bladder cancer. A tool compound that...
BC Extra | Jul 26, 2019
Company News

July 25 Company Quick Takes: RegenxBio, Neurimmune in neurodegenerative gene therapy deal; plus Lilly, Epizyme, ElevateBio and more

RegenxBio partners with Neurimmune, expands gene therapy pipeline  RegenxBio Inc. (NASDAQ:RGNX) and Neurimmune AG (Zurich, Switzerland) partnered to develop and commercialize gene therapies that use the former's NAV vectors to deliver antibodies to treat neurodegenerative...
BC Innovations | Jul 18, 2019
Distillery Therapeutics

Inhibiting EZH2 for myeloma-associated bone loss

DISEASE CATEGORY: Musculoskeletal INDICATION: Bone repair Inhibiting EZH2 could help repair myeloma-associated bone loss. Among 20 myeloma patients in remission, levels of EZH2 mRNA in bone marrow adipocytes, which are associated with bone loss, correlated...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Innovations | Jun 27, 2019
Distillery Therapeutics

Inhibiting EZH2 for colitis and colitis-associated colorectal cancer

DISEASE CATEGORY: Gastrointestinal; cancer INDICATION: Colitis; colorectal cancer Inhibiting EZH2 could help treat colitis and colitis-associated colorectal cancer. The EZH2 inhibitor GSK2816126 or a tool compound EZH2 inhibitor increased survival and colon length, which is...
Items per page:
1 - 10 of 132